Literature DB >> 16416620

Erythroplasia of Queyrat with urethral involvement: treatment with carbon dioxide laser vaporization.

Jesús Pozo Del Losada1, Asunción Ferré, Begoña San Román, Vanessa Vieira, Eduardo Fonseca.   

Abstract

BACKGROUND: Erythroplasia of Queyrat is an uncommon carcinoma in situ that usually arises on the mucosa of the glans penis or prepuce as red, shiny, sharply demarcated velvety plaques. The treatment is often difficult and associated with significant recurrence rates, especially in cases with urethral involvement.
OBJECTIVE: To evaluate carbon dioxide laser treatment in a case of erythroplasia of Queyrat with urethral involvement.
MATERIALS AND METHODS: We report a patient with erythroplasia of Queyrat involving the urethra who was treated with carbon dioxide laser vaporization.
RESULTS: Treatment with carbon dioxide laser vaporization resulted in an excellent cosmetic and functional status outcome for the glans penis and urethral lesions.
CONCLUSION: Carbon dioxide laser vaporization is probably the initial elective treatment for erythroplasia of Queyrat with urethral involvement in young immunocompetent patients. A follow-up is necessary, and new sessions of treatment should be quickly performed if recurrence occurs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16416620     DOI: 10.2310/6350.2005.31217

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

Review 1.  Erythroplasia of Queyrat treated by laser and light modalities: a systematic review.

Authors:  Eric L Maranda; Austin H Nguyen; Victoria M Lim; Vidhi V Shah; Joaquin J Jimenez
Journal:  Lasers Med Sci       Date:  2016-06-21       Impact factor: 3.161

2.  Human papillomavirus 16-positive penile Bowen's disease involving the distal urethra: A case report.

Authors:  Jiro Sakamoto; Kazuyoshi Shigehara; Kyoko Shimizu; Shintaro Maeda; Tomomi Nakagawa; Shohei Kawaguchi; Kouji Izumi; Yoshifumi Kadono; Atsushi Mizokami
Journal:  SAGE Open Med Case Rep       Date:  2020-05-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.